Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.37 |
| ▸ | PTPRB | P23467 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3740215 | 1.00 | JAK2 (0.43) | JAK2JAK1GPR119STSCHRM2 | |
| SCHEMBL3746311 | 0.91 | CHRM2 (0.39) | JAK2JAK1CHRM2CHRM4CHRM1 | |
| SCHEMBL3746315 | 0.91 | CHRM2 (0.39) | JAK2JAK1CHRM2CHRM4CHRM1 | |
| SCHEMBL3749221 | 0.90 | CHRM2 (0.40) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL3631866 | 0.90 | CHRM2 (0.40) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL1835651 | 0.88 | CHRM2 (0.39) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL1835653 | 0.88 | CHRM2 (0.39) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL13980437 | 0.86 | CYP3A4 (0.47) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL3637418 | 0.86 | CYP3A4 (0.47) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL13980457 | 0.84 | JAK2 (0.44) | JAK2JAK1GPR119STSCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-11-18 | — | — | US | claimed |
| EP-1997805-A1 | Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans | Commissariat à l'Energie Atomique (FR) | 2008-12-03 | — | — | EP | claimed |
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-11-18 | — | — | US | disclosed |
| EP-1997805-A1 | Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans | Commissariat à l'Energie Atomique (FR) | 2008-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | ABCB11, TPP1, ABCB1 | JAK2 2665/4885JAK1 2313/4885GPR119 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.